RxDoctor Payments Data

Manju Lakra, MD

Family Medicine · Clemson, SCNPI 1053609644

Payments from drug & device makers

$1,665in general payments, 2019–2025

Across 83 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$466
  • Lilly USA, LLC$176
  • GSK$168
  • Dexcom, Inc.$151
  • AbbVie$148
  • Novartis$112
  • plus $446 from 17 others

What the payments were for

  • Food & beverage$1,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,665 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$289
Medicare patients
19
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$44,626
RybelsusSemaglutide23$42,194
MounjaroTirzepatide31$38,432
OzempicSemaglutide30$35,468
EliquisApixaban42$29,228
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,438
EntrestoSacubitril/Valsartan11$14,302
Tresiba Flextouch U-200Insulin Degludec12$8,726
Atorvastatin Calcium129$2,262
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,038
Omeprazole125$1,399
Albuterol Sulfate HfaAlbuterol Sulfate33$1,363
Celecoxib64$1,276
Losartan Potassium93$1,081
Gabapentin54$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$466$77,66353 claims
Boehringer IngelheimJardiance$15$44,62641 claims
Lilly USA, LLCMounjaro$176$38,43231 claims
PfizerEliquis$25$29,22842 claims
GSKTrelegy Ellipta$168$15,43820 claims
NovartisEntresto$112$14,30211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →